Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lisha Li, Lianglu Wang, Kai Guan, Jun Liu, Daobin Zhou, Yanbin Zhang & Yan Zhang. (2021) Use of Skin Testing Screening and Desensitization Before the First Exposure of Rituximab. Cancer Management and Research 13, pages 9319-9328.
Read now
Read now
Articles from other publishers (28)
Maria Alexandra Velicu, Jose Pedro Lavrador, Naomi Sibtain, Francesco Vergani, Ranjeev Bhangoo, Richard Gullan & Keyoumars Ashkan. (2023) Neurosurgical Management of Central Nervous System Lymphoma: Lessons Learnt from a Neuro-Oncology Multidisciplinary Team Approach. Journal of Personalized Medicine 13:5, pages 783.
Crossref
Crossref
Mihaela Andreescu, Nicoleta Berbec & Alina Tanase. (2023) Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia. Journal of Clinical Medicine 12:7, pages 2731.
Crossref
Crossref
Pan Hao, Chunli Zhang, Huan Ma & Rongfu Wang. (2023) Enhanced tumor inhibiting effect of 131I-BDI-1-based radioimmunotherapy and cytosine deaminase gene therapy modulated by a radio-sensitive promoter in nude mice bearing bladder cancer. Journal of Radiation Research 64:1, pages 85-90.
Crossref
Crossref
Sarah Bailly, Guillaume Cartron, Sridhar Chaganti, Raul Córdoba, Paolo Corradini, Johannes Düll, Isacco Ferrarini, Wendy Osborne, Andreas Rosenwald, Juan‐Manuel Sancho, Hervé Tilly, Eric Van Den Neste, Andreas Viardot & Carlo Visco. (2022) Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper. Hematological Oncology 40:4, pages 505-517.
Crossref
Crossref
Weishang Deng, Sensen Yang, Changyuan Yang, Haitao Chen, Guoning Huang, Hanbiao Wu & Jisheng Chen. (2022) Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience. Journal of Oncology Pharmacy Practice, pages 107815522211104.
Crossref
Crossref
Mariella Della Chiesa, Chiara Setti, Chiara Giordano, Valentina Obino, Marco Greppi, Silvia Pesce, Emanuela Marcenaro, Mariangela Rutigliani, Nicoletta Provinciali, Laura Paleari, Andrea DeCensi, Simona Sivori & Simona Carlomagno. (2022) NK Cell-Based Immunotherapy in Colorectal Cancer. Vaccines 10:7, pages 1033.
Crossref
Crossref
Suheil Albert Atallah-Yunes, Michael J. Robertson, Utpal P. Davé, Paola Ghione & Fabiana Perna. (2022) Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era. Frontiers in Immunology 13.
Crossref
Crossref
Inês Duarte, João Oliveira, Cristina Outerelo, Iolanda Godinho, Marta Pereira, Paulo Fernandes, Sofia Jorge & Joana Gameiro. (2022) Rituximab in glomerular diseases: a case series and narrative review. Brazilian Journal of Nephrology 44:2, pages 187-195.
Crossref
Crossref
Joel Joelsson, Tove Wästerlid, Richard RosenquistLasse Hjort Jakobsen, Tarec C. El-Galaly, Karin E. SmedbySandra Eloranta. (2022) Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Advances 6:8, pages 2657-2666.
Crossref
Crossref
Jeff P Sharman, Carol F Kirchhoff & Robert M Rifkin. (2022) Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study. Future Oncology 18:12, pages 1499-1510.
Crossref
Crossref
Massimiliano Gambella, Simona Carlomagno, Anna Maria Raiola, Livia Giannoni, Chiara Ghiggi, Chiara Setti, Chiara Giordano, Silvia Luchetti, Alberto Serio, Alessandra Bo, Michela Falco, Mariella Della Chiesa, Emanuele Angelucci & Simona Sivori. (2022) CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. Frontiers in Immunology 13.
Crossref
Crossref
Suheil Albert Atallah-Yunes & Michael J. Robertson. (2022) Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. Leukemia Research Reports 17, pages 100319.
Crossref
Crossref
Yu-Chi Chen, Wei Shi, Jia-Jie Shi & Jin-Jian Lu. (2021) Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective. Journal of Cancer Research and Clinical Oncology 148:1, pages 1-14.
Crossref
Crossref
Isabela Werneck da Cunha, Renata de Almeida Coudry, Mariana Petaccia de Macedo, Emilio Augusto Campos Pereira de Assis, Stephen Stefani & Fernando Augusto Soares. (2021) A call to action: molecular pathology in Brazil. Surgical and Experimental Pathology 4:1.
Crossref
Crossref
Jan Škubník, Vladimíra Svobodová Pavlíčková, Tomáš Ruml & Silvie Rimpelová. (2021) Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics. Biology 10:9, pages 849.
Crossref
Crossref
Robert Busch. (2021) Rituximab: A “Magic Bullet” for Treating Some Blood Cancers. Frontiers for Young Minds 9.
Crossref
Crossref
Ji Woong Kim, Yea Bin Cho & Sukmook Lee. (2021) Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 10:3, pages 670.
Crossref
Crossref
Olga Mulas, Giovanni Caocci, Daniela Dessì, Daniela Mantovani, Giulia Moi, Maria Giuseppina Cabras & Giorgio La Nasa. (2021) Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life. Acta Haematologica 144:3, pages 322-326.
Crossref
Crossref
Iago Dillion Lima Cavalcanti & José Cleberson Santos SoaresIago Dillion Lima Cavalcanti & José Cleberson Santos Soares. 2021. Advances in Cancer Treatment. Advances in Cancer Treatment
57
78
.
Arne KolstadTim IllidgeNils BolstadSigne SpetalenUlf MadsbuCaroline Stokke, Johan Blakkisrud, Ayca LøndalenNoelle O'Rourke, Matthew BeasleyWojciech Jurczak, Unn-Merete FagerliMichal KaščákMike BayneAleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal & Harald Holte. (2020) Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances 4:17, pages 4091-4101.
Crossref
Crossref
Giustina Ferone, Myung Chang Lee, Julien Sage & Anton Berns. (2020) Cells of origin of lung cancers: lessons from mouse studies. Genes & Development 34:15-16, pages 1017-1032.
Crossref
Crossref
Bo Jiang, Xiaoyan Ke, Qingyuan Zhang, Wei Xu, Hang Su, Jie Huang, Mingzhi Zhang, Huaqing Wang, Chuan Jin, Jun Zhu, Li Liu, Zhen Cai, Xielan Zhao, Jianfeng Zhou, Xiaohong Zhang, Jing Liu, Hui Zhou, Jie Yu, Xing Sun, Junyuan Qi & Lugui Qiu. (2020) Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study. Scientific Reports 10:1.
Crossref
Crossref
Soo Jin Kim, U Ji Kim, Hae Yong Yoo, Yong June Choi & Keon Wook Kang. (2020) Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences 21:12, pages 4377.
Crossref
Crossref
L. Bergantini, M. d’Alessandro, P. Cameli, L. Vietri, C. Vagaggini, A. Perrone, P. Sestini, B. Frediani & E. Bargagli. (2020) Effects of rituximab therapy on B cell differentiation and depletion. Clinical Rheumatology 39:5, pages 1415-1421.
Crossref
Crossref
Subhayan Chattopadhyay, Guoqiao Zheng, Amit Sud, Kristina Sundquist, Jan Sundquist, Asta Försti, Richard Houlston, Akseli Hemminki & Kari Hemminki. (2019) Second primary cancers in non‐Hodgkin lymphoma: Family history and survival. International Journal of Cancer 146:4, pages 970-976.
Crossref
Crossref
Donmienne Leung, Jacqueline Wurst, Tao Liu, Ruben Martinez, Amita Datta-Mannan & Yiqing Feng. (2020) Antibody Conjugates-Recent Advances and Future Innovations. Antibodies 9:1, pages 2.
Crossref
Crossref
John Puetz & Florian M. Wurm. (2019) Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing. Processes 7:8, pages 476.
Crossref
Crossref
Marisa J. L. Aitken, Hun J. Lee & Sean M. Post. (2019) Emerging treatment options for patients with p53-pathway-deficient CLL. Therapeutic Advances in Hematology 10, pages 204062071989135.
Crossref
Crossref